Predictors of abatacept efficacy in immunomics
Not Applicable
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000041754
- Lead Sponsor
- The University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 105
Inclusion Criteria
Not provided
Exclusion Criteria
Patients treated with more than 3 types of biologics previously Patients with a history of hypersensitivity to any of the ingredients of the abatacept product Patients with a concurrent condition secondary to malignancy Patients with active infection Patients who are pregnant or breastfeeding, or those wishing pregnancy, childbearing, or breastfeeding Patients ineligible for study participation in the opinion of the investigator or subinvestigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Achievement of remission (DAS28-ESR<2.6) or improvement of disease activity (delta-DAS28-ESR>1.2) at Month 6
- Secondary Outcome Measures
Name Time Method